Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
04 mai 2017 08h30 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 4, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that...
Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
01 mai 2017 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 1, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Revenue of $27.6 million in the first quarter of 2017, a 72 percent...
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
24 avr. 2017 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Apr 24, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance
06 mars 2017 08h30 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Mar 6, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) 2016 revenue of $81.3 million, a 62 percent increase from 2015 ...
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance
30 janv. 2017 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jan 30, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) 2016 revenue of $81.3 million, a 62 percent increase from 2015 ...
Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
23 janv. 2017 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jan 23, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2016 financial results and...
Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer
10 déc. 2016 08h30 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Dec 10, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that...
Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
01 nov. 2016 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Nov 1, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Financial Highlights Third quarter revenue of $21.7 million, a...
Corcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host Conference Call
26 oct. 2016 08h30 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Oct 26, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Corcept Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
02 août 2016 16h05 HE | Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Aug 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Second quarter revenue of $19.7 million, a 65 percent increase from the...